Advanced

Cancer Cell Radiobiological Studies Using In-House-Developed α-Particle Irradiator.

Nilsson, Jenny; Bauden, Monika LU ; Nilsson, Jonas LU ; Strand, Sven-Erik LU and Elgqvist, Jörgen LU (2015) In Cancer Biotherapy & Radiopharmaceuticals 30(9). p.386-394
Abstract
An α-particle irradiator, enabling high-precision irradiation of cells for in vitro studies, has been constructed. The irradiation source was a (241)Am source, on which well inserts containing cancer cells growing in monolayer were placed. The total radioactivity, uniformity, and α-particle spectrum were determined by use of HPGe detector, Gafchromic™ dosimetry film, and PIPS(®) detector measurements, respectively. Monte Carlo simulations were used for dosimetry. Three prostate cancer (LNCaP, DU145, PC3) and three pancreatic cancer (Capan-1, Panc-1, BxPC-3) cell lines were irradiated by α-particles to the absorbed doses 0, 0.5, 1, and 2 Gy. For reference, cells were irradiated using (137)Cs to the absorbed doses 0, 1, 2, 4, 6, 8, and 10... (More)
An α-particle irradiator, enabling high-precision irradiation of cells for in vitro studies, has been constructed. The irradiation source was a (241)Am source, on which well inserts containing cancer cells growing in monolayer were placed. The total radioactivity, uniformity, and α-particle spectrum were determined by use of HPGe detector, Gafchromic™ dosimetry film, and PIPS(®) detector measurements, respectively. Monte Carlo simulations were used for dosimetry. Three prostate cancer (LNCaP, DU145, PC3) and three pancreatic cancer (Capan-1, Panc-1, BxPC-3) cell lines were irradiated by α-particles to the absorbed doses 0, 0.5, 1, and 2 Gy. For reference, cells were irradiated using (137)Cs to the absorbed doses 0, 1, 2, 4, 6, 8, and 10 Gy. Radiation sensitivity was estimated using a tetrazolium salt-based colorimetric assay with absorbance measurements at 450 nm. The relative biological effectiveness for α-particles relative to γ-irradiation at 37% cell survival for the LNCaP, DU145, PC3, Capan-1, Panc-1, and BxPC-3 cells was 7.9 ± 1.7, 8.0 ± 0.8, 7.0 ± 1.1, 12.5 ± 1.6, 9.4 ± 0.9, and 6.2 ± 0.7, respectively. The results show the feasibility of constructing a desktop α-particle irradiator as well as indicate that both prostate and pancreatic cancers are good candidates for further studies of α-particle radioimmunotherapy. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Biotherapy & Radiopharmaceuticals
volume
30
issue
9
pages
386 - 394
publisher
Mary Ann Liebert, Inc.
external identifiers
  • pmid:26560194
  • wos:000364485500003
  • scopus:84946908215
ISSN
1557-8852
DOI
10.1089/cbr.2015.1895
language
English
LU publication?
yes
id
dcaff552-c71b-472b-bbc6-675387f332a6 (old id 8235921)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26560194?dopt=Abstract
date added to LUP
2015-12-03 21:55:42
date last changed
2017-02-26 03:05:19
@article{dcaff552-c71b-472b-bbc6-675387f332a6,
  abstract     = {An α-particle irradiator, enabling high-precision irradiation of cells for in vitro studies, has been constructed. The irradiation source was a (241)Am source, on which well inserts containing cancer cells growing in monolayer were placed. The total radioactivity, uniformity, and α-particle spectrum were determined by use of HPGe detector, Gafchromic™ dosimetry film, and PIPS(®) detector measurements, respectively. Monte Carlo simulations were used for dosimetry. Three prostate cancer (LNCaP, DU145, PC3) and three pancreatic cancer (Capan-1, Panc-1, BxPC-3) cell lines were irradiated by α-particles to the absorbed doses 0, 0.5, 1, and 2 Gy. For reference, cells were irradiated using (137)Cs to the absorbed doses 0, 1, 2, 4, 6, 8, and 10 Gy. Radiation sensitivity was estimated using a tetrazolium salt-based colorimetric assay with absorbance measurements at 450 nm. The relative biological effectiveness for α-particles relative to γ-irradiation at 37% cell survival for the LNCaP, DU145, PC3, Capan-1, Panc-1, and BxPC-3 cells was 7.9 ± 1.7, 8.0 ± 0.8, 7.0 ± 1.1, 12.5 ± 1.6, 9.4 ± 0.9, and 6.2 ± 0.7, respectively. The results show the feasibility of constructing a desktop α-particle irradiator as well as indicate that both prostate and pancreatic cancers are good candidates for further studies of α-particle radioimmunotherapy.},
  author       = {Nilsson, Jenny and Bauden, Monika and Nilsson, Jonas and Strand, Sven-Erik and Elgqvist, Jörgen},
  issn         = {1557-8852},
  language     = {eng},
  number       = {9},
  pages        = {386--394},
  publisher    = {Mary Ann Liebert, Inc.},
  series       = {Cancer Biotherapy & Radiopharmaceuticals},
  title        = {Cancer Cell Radiobiological Studies Using In-House-Developed α-Particle Irradiator.},
  url          = {http://dx.doi.org/10.1089/cbr.2015.1895},
  volume       = {30},
  year         = {2015},
}